Medacta Group SA (MOVE) AI Stock Analysis

• Market Cap: CHF3.00B
• Dividend Yield: 0.45%
• Average Volume (3M): 12.13K
• Price to Earnings (P/E): 33.4
• Beta (1Y): 0.85
• Revenue Growth: 16.59%
• EPS Growth: 65.76%
• Country: CH
• Employees: 1,907
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 2.84
• Shares Outstanding: 20,000,000
• 10 Day Avg. Volume: 8,750
• 30 Day Avg. Volume: 12,134
• PEG Ratio: 0.58
• Price to Book (P/B): 5.97
• Price to Sales (P/S): 3.84
• P/FCF Ratio: 924.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF182.00
• Price Target Upside: 8.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: CHF185.00 ▲(10.12% Upside)
• Action: Reiterated Date: 10/31/25
• Date: Action: Reiterated 10/31/25

Medacta Group SA's overall stock score reflects strong financial performance and positive earnings call insights, highlighting robust revenue and profit growth. However, the valuation appears high, and technical indicators suggest a neutral trend. The company's ability to manage costs and maintain growth will be crucial in sustaining its performance.

Positive Factors

Sustained Revenue & Guidance

Clear above-market growth targets and recent H1 outperformance indicate a durable revenue runway driven by product adoption, geographic expansion and potential U.S. manufacturing. Multi-year CAGR guidance frames strategic investments and supports revenue visibility over the next 2–5 years.

Robust Margins and Profitability

High gross and EBITDA margins reflect strong pricing power and efficient cost structure tied to proprietary implants and services. Sustained margin levels support reinvestment in R&D, surgeon training and international expansion, reinforcing long-term competitive advantage in ortho devices.

Solid Balance Sheet & Cash Generation

Strong operating cash generation combined with manageable leverage and improving ROE provides financial flexibility for capex, selective M&A and working capital. This balance underpins durability of operations and the ability to fund strategic initiatives without over-reliance on external financing.

Negative Factors

High Capital Expenditure Pressures

Elevated capex materially limits free cash available for dividends, buybacks or cushioning cyclical downturns. Over the medium term this constrains discretionary investments and increases sensitivity to execution delays or revenue shortfalls, pressuring liquidity and financial flexibility.

H2 Margin Headwinds & Integration Costs

Integration-related costs and increased operating expenses can depress near-term margins and extend the timeline to realize synergies. Persistent integration drag raises the risk that reported profitability will be uneven, complicating planning and potentially slowing reinvestment capacity.

Sustainability of High Growth

High year-over-year comps and reliance on acquisitions to boost growth create execution risk for sustaining top-line momentum. If organic adoption or geographic expansion slows, meeting midterm CAGR targets will require greater execution, elevating strategic and operational risk over the next 2–6 months.

Medacta Group SA Business Overview & Revenue Model

Company Description

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized kinematic models and 3D planning tools for use in hip, knee, shoulder, sports medicine, and spine procedures. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.

How the Company Makes Money

Medacta generates revenue primarily through the sale of orthopedic implants and surgical instruments used in joint replacement and spinal surgeries. The company's core revenue streams include the sale of its proprietary products, which are distributed through a global network of direct sales representatives and independent distributors. Additionally, Medacta offers value-added services such as training and educational programs for surgeons and medical professionals, further enhancing its market presence. Key partnerships with hospitals and surgical centers, along with participation in various orthopedic and medical conferences, also contribute significantly to its earnings by expanding its customer base and promoting its innovative solutions.

Medacta Group SA Financial Statement Overview

Summary

Medacta Group SA exhibits strong financial health with impressive revenue growth and profitability improvements. The balance sheet is stable, with manageable leverage and improved equity returns. However, cash flow from operations is strong, though high capital expenditures limit free cash flow. Continued focus on optimizing capital expenditures could enhance liquidity and financial flexibility.

Income Statement

Medacta Group SA has shown strong revenue growth from 2023 to 2024, with a revenue growth rate of 15.61%. The gross profit margin remains robust at 67.6% for 2024, reflecting efficient cost management and product pricing. Net profit margin improved to 12.34%, indicating enhanced profitability. Both EBIT and EBITDA margins have increased to 15.38% and 27.18% respectively, showcasing strong operational performance. Overall, the income statement indicates healthy growth and profitability.

Balance Sheet

The company's balance sheet demonstrates solid equity growth, with a rise in stockholders' equity from 2023 to 2024. The debt-to-equity ratio remains stable at 0.64, suggesting manageable leverage. Return on equity improved to 19.2%, indicating efficient use of equity to generate profits. The equity ratio stands at 47.92%, reflecting a balanced capital structure. While leverage is within a comfortable range, continued monitoring is advised to maintain financial stability.

Cash Flow

Operating cash flow has increased significantly to 107.1M in 2024, reflecting strong cash generation capabilities. However, free cash flow remains low at 2.45M due to high capital expenditures, potentially impacting liquidity. The operating cash flow to net income ratio is robust at 1.47, indicating effective conversion of profits into cash. The free cash flow to net income ratio is weak at 0.03, suggesting limited cash availability for discretionary uses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	646.07M	590.58M	510.78M	437.12M	363.13M	302.49M
Gross Profit	436.82M	399.44M	347.85M	305.26M	261.25M	214.26M
EBITDA	179.99M	160.51M	119.64M	106.96M	97.81M	81.96M
Net Income	94.93M	72.89M	47.36M	46.25M	51.52M	37.09M
Balance Sheet
Total Assets	860.76M	792.18M	695.87M	584.49M	489.27M	441.94M
Cash, Cash Equivalents and Short-Term Investments	33.24M	31.59M	20.79M	32.26M	20.40M	48.07M
Total Debt	254.83M	241.21M	201.98M	170.25M	132.66M	150.00M
Total Liabilities	436.15M	412.51M	365.83M	309.83M	262.87M	277.22M
Stockholders Equity	424.61M	379.66M	330.04M	274.65M	226.40M	164.72M
Cash Flow
Free Cash Flow	27.06M	2.45M	-7.09M	10.35M	7.57M	32.31M
Operating Cash Flow	138.25M	107.14M	75.13M	73.51M	54.06M	59.59M
Investing Cash Flow	-109.25M	-98.87M	-80.61M	-65.11M	-52.04M	-34.19M
Financing Cash Flow	-14.19M	4.33M	-10.13M	3.44M	-31.21M	-6.03M

Medacta Group SA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 168.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOVE, the sentiment is Neutral. The current price of 168 is above the 20-day moving average (MA) of 156.93, above the 50-day MA of 158.90, and above the 200-day MA of 147.87, indicating a neutral trend. The MACD of -3.54 indicates Positive momentum. The RSI at 42.75 is Neutral, neither overbought nor oversold. The STOCH value of 58.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:MOVE.

Medacta Group SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MOVE	71 Outperform	CHF3.00B	33.45	23.83%	0.45%	16.59%	65.76%
YPSN	70 Outperform	CHF4.09B	21.10	27.15%	0.67%	27.63%	160.67%
STMN	66 Neutral	CHF15.49B	43.51	―	1.02%	4.49%	45.08%
TECN	65 Neutral	CHF1.74B	27.33	4.57%	2.31%	-9.34%	-37.50%
MED	62 Neutral	CHF1.27B	-2,397.96	―	―	7.29%	-112.70%
KURN	61 Neutral	CHF1.00B	-163.70	-7.82%	―	104.01%	33.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medacta Group SA Corporate Events

Medacta Delivers 18.5% Constant-Currency Revenue Growth in 2025 on Broad-Based Demand

Medacta Group SA reported another year of robust, above-market expansion in 2025, with preliminary unaudited revenue rising 18.5% in constant currency (15.8% in euro) to €683.8 million, driven by double-digit growth in all major regions and product lines. Asia-Pacific and North America led geographic performance with growth of 23.0% and 19.0% respectively, while Latin America surged 42.2%, and the acquisition and integration of Parcus Medical contributed roughly 1.5% to group sales; across business lines, knee and extremities posted particularly strong increases, supported by Medacta’s AMIS hip platform, Kinematic Alignment and GMK SpheriKA knee technologies, and NextAR augmented reality systems in shoulder and spine, underscoring the company’s innovation-led growth strategy, ongoing supply-chain optimization through a new automated warehouse in Italy, and continued investment in its global workforce with the creation of 258 new jobs.

The most recent analyst rating on (CH:MOVE) stock is a Buy with a CHF183.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.